In a recent study by Song et al. (2025), four patients with generalized myasthenia gravis (gMG) were treated with a new therapy called telitacicept over an 8-week period. This treatment targets specific molecules involved in the immune response. After treatment, all patients showed significant improvements in their symptoms and quality of life, as measured by three different scales. These scales assessed disease severity, impact on daily life, and overall quality of life.
Furthermore, the study reported a decrease in certain immune cells and antibodies associated with gMG, suggesting that telitacicept effectively modulates the immune system. Only one patient experienced a mild side effect related to the injection. While these initial results are promising, Song et al. emphasize the need for more extensive research to confirm the benefits and safety of telitacicept for a broader patient population.
More Info 
Add to Calendar 